Is Ephedrine legal in Japan?

Legal status

Ephedrine is controlled in Japan as a 覚醒剤原料, a stimulant raw material, under the Stimulants Control Act, subject to the ten per cent exclusion below. 第二条第五項 provides 「この法律で「覚醒剤原料」とは、別表に掲げる物をいう。」 and the entry is 「一―フエニル―二―メチルアミノプロパノール―一、その塩類及びこれらのいずれかを含有する物。ただし、一―フエニル―二―メチルアミノプロパノール―一として一〇％以下を含有する物を除く。」 at 覚醒剤取締法別表第一号, which is 1-phenyl-2-methylaminopropanol-1, its salts and anything containing them, except a thing containing ten per cent or less of it. That name covers both ephedrine and pseudoephedrine, and the Narcotics Control Department's list enters them together as «Ephedrine, Pseudoephedrine» with the same ten per cent exclusion. It is not a 覚醒剤, and the raw material offences are a separate and lighter set. Methylephedrine is a separate raw material at 別表第三号, and the Act's 別表第九号 lets further raw materials be added by Cabinet Order, which the stimulant raw material Cabinet Order (覚醒剤原料を指定する政令) has done. The position is as at 2 October 2026 on e-Gov. It is in neither the narcotics tables status 6 September 2026 nor the psychotropics tables status 3 October 2025, and a search of the designated substances list status 6 September 2026 for エフェドリン and ephedrine returned nothing.

Consequences if caught

Capital exposure: none. No Japanese drug statute provides a death sentence: 死刑 appears in the main provisions of none of the 麻薬及び向精神薬取締法 (the Narcotics and Psychotropics Control Act), the 覚醒剤取締法 (the Stimulants Control Act), the あへん法 (the Opium Act), the 大麻草の栽培の規制に関する法律 (the Cannabis Plant Cultivation Act), the pharmaceuticals Act (the PMD Act) or the 麻薬特例法 (the Narcotics Special Provisions Act), each read on e-Gov on 2 October 2026. Japan has not abolished capital punishment: 刑法第九条 lists it among the principal punishments, 「死刑、拘禁刑、罰金、拘留及び科料を主刑とし、没収を付加刑とする。」, and 第百九十九条 provides it for murder. Every penalty below reads 拘禁刑, the single form of imprisonment that replaced 懲役 and 禁錮 on the day described in the ministerial ordinance's own words as 「刑法等の一部を改正する法律の施行の日（令和七年六月一日）」, 1 June 2025; under 刑法第十二条第一項 「有期拘禁刑は、一月以上二十年以下とする。」, so an open ended fixed term such as one year or more runs to twenty years, and 第十四条第二項 allows an aggravated fixed term to rise to thirty. The drug statutes took the new term from 令和四年法律第六十八号. Life imprisonment appears in the drug statutes in three places only: 麻薬及び向精神薬取締法第六十四条第二項 (heroin imported, exported or made for profit), 覚醒剤取締法第四十一条第二項 (stimulants imported, exported or made for profit) and 麻薬特例法第五条 (dealing in any 規制薬物 as a business). Importing or exporting ephedrine in breach of 第三十条の六, or manufacturing it in breach of 第三十条の八, is 覚醒剤取締法第四十一条の三第一項, 「次の各号のいずれかに該当する者は、十年以下の拘禁刑に処する。」, up to ten years, and at least one year with a fine of up to five million yen where the circumstances warrant if done for profit. Possessing it in breach of 第三十条の七, transferring or receiving it in breach of 第三十条の九第一項, or using it in breach of 第三十条の十一 is 第四十一条の四第一項, 「次の各号のいずれかに該当する者は、七年以下の拘禁刑に処する。」, up to seven years, and up to ten with a fine of up to three million yen for profit. Use is in the seven year group, not the ten year one. A 覚醒剤原料 is not a 規制薬物 under 麻薬特例法第二条第一項, so that Act's life term does not reach it. A medicine at or below ten per cent ephedrine is outside the raw material definition altogether.

If prescribed or medical

Ephedrine medicines above the ten per cent line can be held by a patient: 第三十条の七第十一号 and 第十二号 allow a person who received a 医薬品である覚醒剤原料 from a doctor or on a prescription to possess it. A foreign prescription is not that and does not of itself make the medicine importable.

Documentation

A foreign prescription does not make an ephedrine medicine importable, and a medicine above ten per cent ephedrine or pseudoephedrine needs the Minister's advance permission under 覚醒剤取締法第三十条の六第一項, 「ただし、本邦に入国する者が、厚生労働大臣の許可を受けて、自己の疾病の治療の目的で携帯して医薬品である覚醒剤原料を輸入する場合は、この限りでない。」 第三十条の六第二項 then treats the traveller as a patient: 「前項ただし書の規定により、医薬品である覚醒剤原料を携帯して輸入した者は、第三十条の七（所持の禁止）、第三十条の九第一項（譲渡及び譲受の制限及び禁止）又は第三十条の十一（使用の禁止）の規定の適用については、病院若しくは診療所において診療に従事する医師若しくは歯科医師又は医療法第五条第一項（往診医師等に関する特例）に規定する医師若しくは歯科医師（以下「往診医師等」という。）から施用のため医薬品である覚醒剤原料の交付を受けた者とみなす。」 The Narcotics Control Department names pseudoephedrine as an example of a raw material that needs that permission, says «You should apply at least 14 days prior to your travel.» and requires the medicine to be carried personally. A product at or below ten per cent is not a 覚醒剤原料 and falls to the general personal import rule. Placement relied on: 覚醒剤取締法別表 as at 2 October 2026 on e-Gov.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Japan’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.